This comes after both Maccabi and Meuhedet Health Services announced the same subsidy for the Mounjaro weight loss shot.

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also increasing in popularity as weight-loss options for people around the world. When ...

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Following Wegovy's success, Eli Lilly introduced Zepbound after receiving US Food and Drug Administration (FDA) approval in November 2023. Zepbound, also known as Mounjaro outside the US ...